ABSTRACT
INTRODUCTION
Resulting abnormalities in retinal morphology from VMT commonly lead to visual decline, including metamorphopsia, visual field defect, and decreased visual acuity [3] . Surgical management with pars plana vitrectomy (PPV) has long been the mainstay of VMT and FTMH treatment [4, 5] . However, following the U.S. Iselin, NJ, USA) for the treatment of VMT, pharmacologic vitreolysis is now a viable therapeutic option. Ocriplasmin, a 27 kilodalton serine protease, achieves its effect via lysis of laminin and fibronectin at the vitreoretinal interface and subsequent VMA release [6] .
As a first-in-class drug, clinical understanding of ocriplasmin continues to evolve over time. Experience from phase III clinical trials and subsequent post-marketing clinical series have provided added information regarding the efficacy of ocriplasmin, expected ''real-world'' outcomes, patient selection, and adverse event profiles. These topics are reviewed below. 
Compliance with Ethics Guidelines
This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors. 
EFFICACY OF OCRIPLASMIN: CLINICAL TRIAL EVIDENCE

Macular Hole Closure
In the MIVI-TRUST trials, overall nonsurgical macular hole closure rate was noted to be 40.6% with ocriplasmin treatment, with success noted for both small (58.3% versus 16.0%, p\0.001) and medium (36.8% versus 5.3%, p = 0.009) holes. However, ''real world'' outcomes of hole closure have been lower than that found in the MIVI-TRUST trials, including in series with small and medium sized FTMH. For instance, Miller et al. [16] and Sharma et al. [14] reported a hole closure rates of 12.5% (1/8 eyes) and 28.6% (4/14 eyes), respectively, despite that macular holes were sized \400 lm.
Further subgroup analysis of macular hole cases has revealed additional insights. For instance, Dugel et al. [17] however, a precise mechanism for these adverse events and why such changes occur in only selected patients is currently uncertain.
OCULAR ADVERSE EVENTS
Categories of Adverse Events
The [26] .
Considering data from the MIVI-TRUST trials non-standardized follow-up reporting [25] .
Caution should be applied to evaluation of this information, as it may be subject to over-interpretation, under-reporting, selection bias, and recall bias.
Optical Coherence Tomography Changes
Post-Ocriplasmin Use 
Electroretinogram Changes Post-Ocriplasmin Use
A total of 18 reports of ERG changes were noted in the MIVI-TRUST data, TSC analysis, and survey of Shah et al. combined [6, 25, 26] .
Two case reports with full-field ERG findings are also available in the literature, one with and one without FTMH. [21, 22] Findings were notable for reduction in B wave amplitudes during the scotopic ERG. Although A wave and photopic abnormalities were also present, the authors reported ERG findings were thought to be most consistent with bipolar cell dysfunction and reduced activity in primarily rod photoreceptors.
The ERG sub-study of the OASIS trial was completed to further clarify and describe ERG changes over the 24-month follow-up period Long-term ramifications of OCT and ERG abnormalities are not fully known and continue to be investigated, but appear to be related to pharmacologic VMT release with ocriplasmin.
The interesting lack of correlation with ultimate visual acuity outcomes is also interesting and worth noting. To date, all cases with reported long-term outcomes have been transient with restoration of visual acuity [10, 20, 22, 23, 27] .
VITRECTOMY OUTCOMES FOLLOWING OCRIPLASMIN USE
Vitrectomy has been shown to be an effective treatment option for patients with VMT, with well-characterized rare adverse events including infection, hemorrhage, retinal detachment, macular hole, and loss of vision [4, 5] (Fig. 3) . In a multicenter, controlled interventional series, 
